Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical companies, which includes the makers of Xarelto, possess a duty to ensure that their drugs are reasonably safe for use – and failure to complete so may be grounds for compensation. Our lawyers are functioning tough to get those hurt by the drug the compensation they may be entitled to.
Whilst bleeding can be a common complication associated with anticoagulants, it has been alleged that Xarelto is far more dangerous than standard blood thinners due to the fact no antidote exists to reverse its blood-thinning effects. This implies that, inside the event of an emergency, individuals might be at risk for irreversible bleeding difficulties, like life-threatening internal and gastrointestinal hemorrhaging.
If you or even a loved one particular suffered a serious bleeding event after taking Xarelto, you may have legal recourse. For far more data, contact us right now to have your case reviewed, cost-free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are looking for compensation from Bayer and Janssen for previous and future healthcare bills, lost wages, discomfort and suffering and, in cases of death, funeral expenses. Additionally, they are in search of punitive damages, that are normally awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Becoming Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike conventional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective implies of stopping Xarelto users from bleeding inside the occasion of an emergency. Plaintiffs within the lawsuits allege significant and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user within the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing unsafe clotting.
Visit this http://blog.nkhs.tp.edu.tw/highscope/post/7/106 page for much more details on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.